Healthcare · Biotechnology
Price
$40.50
Market Cap
$6.3B
Employees
77
Beta
1.12
Avg Volume
2,897,233
CEO
Mario Alberto Accardi
Business Description
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-27.74
Stock Price: $40.50
EPS (Diluted): -1.46
EPS (Diluted): -1.46
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
6.44
Stock Price: $40.50
Total Equity: $526.86M
Shares: 135,715,608
Total Equity: $526.86M
Shares: 135,715,608
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-23.84
Market Cap: $6.27B
Total Debt: $7.57M
Cash: $61.30M
EBITDA: -$183.33M
Total Debt: $7.57M
Cash: $61.30M
EBITDA: -$183.33M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$3.3B
Market Cap: $6.27B
Total Debt: $7.57M
Cash: $61.30M
Total Debt: $7.57M
Cash: $61.30M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
226.28
Stock Price: $40.50
Revenue: $15.00M
Shares: 135,715,608
Revenue: $15.00M
Shares: 135,715,608
EV/Sales (Total value vs revenue — works when P/E can't)
API222.70
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
100.0%
Gross Profit: $15.00M
Revenue: $15.00M
Revenue: $15.00M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-1,384.6%
Operating Income: -$207.69M
Revenue: $15.00M
Revenue: $15.00M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-1,316.9%
Net Income: -$197.53M
Revenue: $15.00M
Revenue: $15.00M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-60.4%
Net Income: -$197.53M
Total Equity: $526.86M
Total Equity: $526.86M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-42.4%
Operating Income: -$207.69M
Tax Rate: -0.9%
Equity: $526.86M
Total Debt: $7.57M
Cash: $61.30M
Tax Rate: -0.9%
Equity: $526.86M
Total Debt: $7.57M
Cash: $61.30M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
8.57
Current Assets: $367.88M
Current Liabilities: $42.94M
Current Liabilities: $42.94M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.01
Short-Term Debt: $0.00
Long-Term Debt: $7.57M
Total Debt: $7.57M
Total Equity: $526.86M
Long-Term Debt: $7.57M
Total Debt: $7.57M
Total Equity: $526.86M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.11
Revenue: $15.00M
Shares: 135,715,608
Shares: 135,715,608
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$3.88
Total Equity: $526.86M
Shares: 135,715,608
Shares: 135,715,608
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.43
Operating CF: -$193.82M
CapEx: -$371,000
Shares: 135,715,608
CapEx: -$371,000
Shares: 135,715,608
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $40.50
Stock Price: $40.50
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$197.53M
Net Income: -$197.53M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CNTA against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:40pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $6.9M | $0 | $15.0M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $6.9M | $0 | $15.0M |
| Operating Expenses | $374.9M | $212.3M | $178.1M | $201.1M | $222.7M |
| Operating Income | -$374.9M | -$212.3M | -$171.3M | -$201.1M | -$207.7M |
| Net Income | -$381.9M | -$216.2M | -$151.1M | -$235.8M | -$197.5M |
| EBITDA | -$139.3M | -$209.5M | -$165.4M | -$221.9M | -$183.3M |
| EPS | $-4.24 | $-2.31 | $-1.57 | $-2.06 | $-1.46 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:40pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $595.1M | $393.6M | $128.0M | $383.2M | $61.3M |
| Total Current Assets | $628.8M | $437.7M | $315.1M | $536.4M | $367.9M |
| Total Assets | $629.6M | $444.3M | $360.2M | $576.8M | $687.5M |
| Current Liabilities | $24.6M | $38.3M | $39.4M | $58.0M | $42.9M |
| Long-Term Debt | $75.7M | $69.8M | $75.7M | $108.9M | $7.6M |
| Total Liabilities | $138.1M | $108.1M | $124.0M | $175.3M | $160.6M |
| Total Equity | $491.6M | $336.2M | $236.2M | $401.5M | $526.9M |
| Retained Earnings | -$385.7M | -$601.9M | -$752.9M | -$988.7M | -$1.2B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:40pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$136.1M | -$200.5M | -$160.3M | -$142.1M | -$193.8M |
| Capital Expenditure | $-185,982 | -$1.1M | $-169,000 | $-34,000 | $-371,000 |
| Free Cash Flow | -$136.3M | -$201.7M | -$160.5M | -$142.1M | -$194.2M |
| Acquisitions (net) | $63.4M | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $-11,998 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $590.1M | -$201.4M | -$265.6M | $255.2M | -$321.3M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 9:34am (32m ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$25.0M $25.0M – $25.0M
|
$219.9M $219.9M – $219.9M
|
$495.7M $495.7M – $495.7M
|
$882.6M $882.6M – $882.6M
|
| EBITDA |
$5.0M $5.0M – $5.0M
|
$44.0M $44.0M – $44.0M
|
$99.1M $99.1M – $99.1M
|
$176.5M $176.5M – $176.5M
|
| Net Income |
-$236.4M -$260.4M – -$212.4M
|
-$161.5M -$323.2M – $175.0M
|
$110.4M $110.4M – $110.4M
|
$361.9M $361.9M – $361.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:40pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | -100.0% | — |
| Gross Profit Growth | — | — | -100.0% | — |
| Operating Income Growth | +43.4% | +19.3% | -17.4% | -3.3% |
| Net Income Growth | +43.4% | +30.1% | -56.0% | +16.2% |
| EBITDA Growth | -50.4% | +21.1% | -34.1% | +17.4% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 9:34am (32m ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-24 | Medicxi Ventures Management (Jersey) Ltd | S-Sale | 281,162.00 | $38.00 | $10.7M |
| 2026-06-24 | INDEX VENTURES LIFE VI (JERSEY) L.P. | S-Sale | 149,421.00 | $38.00 | $5.7M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 5,500.00 | $38.00 | $209,000 |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 221,559.00 | $5.84 | $1.3M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 166,779.00 | $9.42 | $1.6M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 100,000.00 | $20.00 | $2.0M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 160,000.00 | $9.53 | $1.5M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 100,000.00 | $3.85 | $385,000 |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 170,000.00 | $8.01 | $1.4M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 175,000.00 | $16.90 | $3.0M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 160,000.00 | $25.19 | $4.0M |
| 2026-06-24 | Bush Tia L | D-Return | 147,954.00 | $38.00 | $5.6M |
| 2026-06-24 | Bush Tia L | D-Return | 360,338.00 | $9.42 | $3.4M |
| 2026-06-24 | Bush Tia L | D-Return | 140,000.00 | $9.53 | $1.3M |
| 2026-06-24 | Bush Tia L | D-Return | 27,187.00 | $3.85 | $104,670 |
| 2026-06-24 | Bush Tia L | D-Return | 145,208.00 | $8.01 | $1.2M |
| 2026-06-24 | Bush Tia L | D-Return | 125,000.00 | $16.90 | $2.1M |
| 2026-06-24 | Bush Tia L | D-Return | 140,000.00 | $25.19 | $3.5M |
| 2026-06-24 | Crowley John J | D-Return | 45,000.00 | $38.00 | $1.7M |
| 2026-06-24 | Crowley John J | D-Return | 600,000.00 | $8.80 | $5.3M |
Dividend History (Last 20)
Last updated: Jun 21, 2026 7:40pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-24 | $38.00 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for CNTA — it's generated by the pipeline (
market-narrative step).
No community reviews yet for CNTA.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30